Patients treated with aminoglycosides by any route should be under close clinical observation because of the potential toxicity associated with their use. As with other aminoglycosides, the major toxic effects of kanamycin sulfate are its action on the auditory and vestibular branches of the eighth nerve and the renal tubules. Neurotoxicity is manifested by bilateral auditory toxicity which often is permanent and, sometimes, by vestibular ototoxicity. Loss of high frequency perception usually occurs before there is noticeable clinical hearing loss and can be detected by audiometric testing. There may not be clinical symptoms to warn of developing cochlear damage. Vertigo may occur and may be evidence of vestibular injury. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. The risk of hearing loss increases with the degree of exposure to either high peak or high trough serum concentrations and continues to progress after drug withdrawal.
Renal impairment may be characterized by decreased creatinine clearance, the presence of cells or casts, oliguria, proteinuria, decreased urine specific gravity, or evidence of increasing nitrogen retention (increasing BUN, NPN, or serum creatinine).
The risks of severe ototoxic and nephrotoxic reactions are sharply increased in patients with impaired renal function and in those with normal renal function who receive high doses or prolonged therapy.
Renal and eighth nerve function should be closely monitored, especially in patients with known or suspected reduced renal function at the onset of therapy, and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Serum concentrations of parenterally administered aminoglycosides should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels. Urine should be examined for decreased specific gravity, increased excretion of protein and the presence of cells or casts. Blood urea nitrogen, serum creatinine, or creatinine clearance should be measured periodically. Serial audiograms should be obtained when feasible in patients old enough to be tested, particularly high risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears, and hearing loss) or nephrotoxicity requires dosage adjustment or discontinuance of the drug.
Neuromuscular blockade with respiratory paralysis may occur when kanamycin sulfate is instilled intraperitoneally concomitantly with anesthesia and muscle-relaxing drugs. Neuromuscular blockade has been reported following parenteral injection and the oral use of aminoglycosides. The possibility of the occurrence of neuromuscular blockade and respiratory paralysis should be considered if aminoglycosides are administered by any route, especially in patients receiving anesthetics, neuromuscular-blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood. If blockage occurs, calcium salts may reduce these phenomena but mechanical respiratory assistance may be necessary.
The concurrent and/or sequential systemic, oral, or topical use of kanamycin and other potentially nephrotoxic, and/or neurotoxic drugs, particularly polymyxin B, bacitracin, colistin, amphotericin B, cisplatin, vancomycin, and all other aminoglycosides (including paromomycin) should be avoided because the toxicity may be additive. Other factors which may increase patient risk of toxicity are advanced age and dehydration.
Kanamycin sulfate should not be given concurrently with potent diuretics (ethacrynic acid, furosemide, meralluride sodium, sodium mercaptomerin, or mannitol). Some diuretics themselves cause ototoxicity, and intravenously administered diuretics may enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.
(Kanamycin Injection, USP)
1 g per 3 mL
Kanamycin sulfate is an aminoglycoside antibiotic produced by Streptomyces kanamyceticus. It is C18H36N4O11• 2H2SO4.D-Streptamine, O-3-amino-3-deoxy-α-D-glucopyranosyl • (1→6)-O- [6-amino-6-deoxy-α-D-glucopyranosyl- (1→4)]-2-deoxy, sulfate 1:2 (salt). It consists of two amino sugars glycosidically linked to deoxystreptamine.
Kanamycin is indicated in the short term treatment of serious infections caused by susceptible strains of the designated microorganisms below. Bacteriological studies to identify the causative organisms and to determine their susceptibility to kanamycin should be performed. Therapy may be instituted prior to obtaining the results of susceptibility testing.
Kanamycin may be considered as initial therapy in the treatment of infections where one or more of the following are the known or suspected pathogens: E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species. The decision to continue therapy with the drug should be based on results of the susceptibility tests, the response of the infection to therapy, and the important additional concepts contained in the WARNING box above.
In serious infections when the causative organisms are unknown, KANTREX may be administered as initial therapy in conjunction with a penicillin- or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected, consideration should be given to using other suitable antimicrobial therapy in conjunction with kanamycin.
Although kanamycin is not the drug of choice for staphylococcal infections, it may be indicated under certain conditions for the treatment of known or suspected staphylococcal disease. These situations include the initial therapy of severe infections where the organism is thought to be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and mixed staphylococcal/Gram-negative infections.
Published Studies Related to Kantrex (Kanamycin)
Effects of prolonged kanamycin administration on cochlear anatomy and auditory brainstem response thresholds in chickens. [2008.05]
OBJECTIVE: To determine whether regenerated hair cells in the basilar papilla of chickens are resistant to kanamycin monosulfate damage... CONCLUSION: The immature regenerated hair cells in the basilar papilla of chickens are resistant to kanamycin ototoxic effects; however, this resistance is not seen in mature hair cells following prolonged kanamycin exposure.
Topical kanamycin: an effective therapeutic option in aerobic vaginitis. [2006.08]
Eighty-one patients with clinical diagnosis of aerobic vaginitis (AV) were included in the study. The patients were randomized for treatment, 45 with kanamycin (100 mg vaginal ovules for 6 days, consecutively) and 36 with meclocycline (35 mg vaginal ovules for 6 days, consecutively)... In conclusion, our data suggest that the topical use of kanamycin could be considered a specific antibiotic for the therapy of this new pathology.
Clinical Trials Related to Kantrex (Kanamycin)
Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics [Recruiting]
High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis [Completed]
The need for a standardized treatment protocol for multidrug resistant tuberculosis (MDR-TB)
in resource-limited countries is being increasingly recognized. This single center, double
blind, randomized controlled trial was designed to compare the time required for sputum
culture conversion and extent of radiological improvement in cases of MDR pulmonary
tuberculosis when isoniazid was included (both at a regular dose and at a high dose) as an
adjuvant to the standardized second line of treatment. The study was designed to test the
hypothesis that inclusion of high-dose isoniazid will enhance the effectiveness of the second
line of treatment in cases of MDR-TB without significantly increasing the toxicity.
Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis [Recruiting]
This study, conducted jointly by researchers at the National Masan TB Hospital, Asan and
Samsung Medical Centers in Seoul, Republic of Korea, and the Yonsei University and the NIH
in the United States, will examine why some patients with tuberculosis (TB) develop disease
that is harder to treat than most cases. TB is an infection of the lung that usually can be
successfully treated with anti-TB drugs. However, some people get a more serious kind of
disease (called multi-drug resistant TB or extensively drug-resistant TB) that is very
difficult to treat and may not be cured by the regular medicines available. This study will
try to find out if some of the common TB drugs are getting to the place where the TB
bacteria are. It will also look at how current anti-TB drugs might be used more effectively
and how better drugs might be developed.
People 20 years of age and older with hard-to-treat TB who have elected to undergo surgical
removal of part of their lung at the National Masan Tuberculosis Hospital, Masan, the Asan
Medical Center, and the Samsung Medical Center, may be eligible for this study.
Participants undergo the following procedures:
- Medical history and physical examination, including sputum sample.
- Blood tests at various times during the study.
- Drug administration. Subjects are given one dose each of five common TB drugs -
rifampicin, isoniazid, pyrazinamide, kanamycin and moxifloxacin - before they undergo
surgery to remove part of their lung. After surgery, some of the lung tissue and fluid
around the lungs that was removed during surgery will be examined to determine the
regions where the TB bacteria live and analyze the lung tissue itself.
- Dynamic MRI (magnetic resonance imaging) scan. This type of scan uses a magnetic field
and radio waves to produce pictures of the lung. Subjects lie very still on a table
inside the cylindrical scanner with their head on a soft cradle and their hands over
their head. Several images are obtained for less than 5 minutes at a time.
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease [Active, not recruiting]
OBJECTIVES: I. Determine the bacteriological activity of amithiozone against Mycobacterium
avium complex (MAC) pulmonary disease.
II. Define the ability of amithiozone to improve clinical outcomes in patients with MAC
III. Determine the safety and tolerance of amithiozone with chronic dosing in these
IV. Assess the contribution of clarithromycin, streptomycin, rifampin, ethambutol,
kanamycin, and amithiozone in the treatment of pulmonary MAC infection.
Page last updated: 2008-06-22